CoChat

Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain

Nord, Magdalena, Finnema, Sjoerd J., Halldin, Christer, Farde, Lars · 2013 · International Journal of Neuropsychopharmacology
Cited by 92

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for treatment of psychiatric disorders. The exact mechanism underlying the clinical effects of SSRIs remains unclear, although increased synaptic serotonin concentrations have been hypothesized to be an initial step. [11C]AZ10419369 is a novel 5-HT1B receptor selective radioligand, which is sensitive to changes in endogenous serotonin concentrations. To assess whether a single dose of the SSRI escitalopram affects endogenous serotonin concentrations in serotonergic projection areas and in the raphe nuclei (RN), three cynomolgus monkeys and nine human subjects underwent PET examinations with [11C]AZ10419369 at baseline conditions and after escitalopram administration. In monkeys, the binding potential (BPND) was significantly lower post dose compared to baseline in dorsolateral prefrontal cortex, occipital cortex, thalamus, midbrain and RN (p < 0.05). In humans, the BPND tended to decrease in RN post dose (p = 0.08). In all serotonergic projection areas, the BPND was conversely higher post dose compared to baseline. The increase was significant in a combined region of all projection areas (p = 0.01) and in occipital and temporal cortex (p < 0.05). SSRIs are generally assumed to elevate endogenous serotonin concentrations in projection areas, evoking the antidepressant effect. In the present study, a single, clinically relevant, dose of escitalopram was found to decrease serotonin concentrations in serotonergic projection areas in humans. Hypothetically, desensitization of inhibitory serotonergic autoreceptors will cause the serotonin concentration in projection areas to increase over time with chronic administration. Thus, the findings in the present study might aid in understanding the mechanism of SSRIs' delayed onset of clinical effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145712001617

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 33

  1. Bel, 1992, Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study, Eur J Pharmacol, 229, 101, 10.1016/0014-2999(92)90292-C · DOI · Paper page
  2. Bel, 1993, Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei, Synapse, 15, 243, 10.1002/syn.890150310 · DOI · Paper page
  3. Bergstrom, 1981, Head fixation device for reproducible position alignment in transmission CT and positron emission tomography, J Comput Assist Tomogr, 5, 136, 10.1097/00004728-198102000-00027 · DOI · Paper page
  4. Breaud, 2009, A rapid and reliable method for the quantitation of tricyclic antidepressants in serum using HPLC-MS/MS, Clin Biochem, 42, 1300, 10.1016/j.clinbiochem.2009.05.006 · doi:10.1016/j.clinbiochem.2009.05.006
  5. Derry, 2006, Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy, Neuroimage, 30, 341, 10.1016/j.neuroimage.2005.09.052 · DOI
  6. Finnema, 2010, Fenfluramine-induced serotonin release decreases [(11)C]AZ10419369 binding to 5-HT(1B)-receptors in the primate brain, Synapse, 64, 573, 10.1002/syn.20780 · DOI · Paper page
  7. Finnema, 2012, Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach, J Cereb Blood Flow Metab, 32, 685, 10.1038/jcbfm.2011.172 · DOI · Paper page
  8. Fuller, 1994, Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis, Life Sci, 55, 163, 10.1016/0024-3205(94)00876-0 · DOI · Paper page
  9. Hervas, 1998, Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors, Eur J Pharmacol, 358, 9, 10.1016/S0014-2999(98)00579-2 · DOI
  10. Invernizzi, 1992, Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex, Brain Res, 584, 322, 10.1016/0006-8993(92)90914-U · DOI · Paper page
  11. Invernizzi, 1994, Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors, Eur J Pharmacol, 260, 243, 10.1016/0014-2999(94)90344-1 · DOI
  12. Jovanovic, 2006, A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria, Psychiatry Res, 148, 185, 10.1016/j.pscychresns.2006.05.002 · DOI
  13. Juan, 2005, Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI), J Chromatogr B Analyt Technol Biomed Life Sci, 820, 33, 10.1016/j.jchromb.2005.03.006 · doi:10.1016/j.jchromb.2005.03.006
  14. Kirchherr, 2006, Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach, J Chromatogr B Analyt Technol Biomed Life Sci, 843, 100, 10.1016/j.jchromb.2006.05.031 · DOI · Paper page
  15. Maier, 2009, [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy, J Pharmacol Exp Ther, 330, 342, 10.1124/jpet.109.150722 · DOI
  16. Meltzer, 1989, Serotonergic dysfunction in depression, Br J Psychiatry, 155, 25, 10.1192/S0007125000291733 · DOI · Paper page
  17. Milak, 2011, In vivo serotonin-sensitive binding of [11C]CUMI-101: a serotonin 1A receptor agonist positron emission tomography radiotracer, J Cereb Blood Flow Metab, 31, 243, 10.1038/jcbfm.2010.83 · DOI · Paper page
  18. Owens, 1994, Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter, Clin Chem, 40, 288, 10.1093/clinchem/40.2.288 · DOI · Paper page
  19. Paterson, 2010, Measuring endogenous 5-HT release by emission tomography: promises and pitfalls, J Cereb Blood Flow Metab, 30, 1682, 10.1038/jcbfm.2010.104 · DOI · Paper page
  20. Pierson, 2008, [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain, Neuroimage, 41, 1075, 10.1016/j.neuroimage.2008.02.063 · DOI
  21. Pineyro, 1999, Autoregulation of serotonin neurons: role in antidepressant drug action, Pharmacol Rev, 51, 533
  22. Reis, 2007, Therapeutic drug monitoring of escitalopram in an outpatient setting, Ther Drug Monit, 29, 758, 10.1097/FTD.0b013e31815b3f62 · DOI · Paper page
  23. Ressler, 2000, Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders, Depress Anxiety, 12, 2, 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4 · doi:10.1002/1520-6394(2000)12:1+<2::aid-da2>3.0.co;2-4
  24. Ridler, 2011, Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: a positron emission tomography study in Papio anubis, Synapse, 65, 1119, 10.1002/syn.20946 · DOI
  25. Romero, 1997, Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors, J Neurochem, 68, 2593, 10.1046/j.1471-4159.1997.68062593.x · DOI · Paper page
  26. Romero, 1996, Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain, Neuropsychopharmacology, 15, 349, 10.1016/0893-133X(95)00240-E · DOI · Paper page
  27. Sari, 2004, Serotonin1B receptors: from protein to physiological function and behavior, Neurosci Biobehav Rev, 28, 565, 10.1016/j.neubiorev.2004.08.008 · DOI · Paper page
  28. Schain, 2012, Quantification of serotonin transporter availability with [11C]MADAM–a comparison between the ECAT HRRT and HR systems, Neuroimage, 60, 800, 10.1016/j.neuroimage.2011.12.047 · DOI
  29. Selvaraj, 2012, Measuring endogenous changes in serotonergic neurotransmission in humans: a [(11)C]CUMI-101 PET challenge study, Mol Psychiatry, 17, 1254, 10.1038/mp.2012.78 · DOI
  30. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59, 22
  31. Varnas, 2011, Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain, J Cereb Blood Flow Metab, 31, 113, 10.1038/jcbfm.2010.55 · DOI · Paper page
  32. Varrone, 2009, Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT, Eur J Nucl Med Mol Imaging, 36, 1639, 10.1007/s00259-009-1156-3 · DOI · Paper page
  33. Varrone, 2011, Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates, J Nucl Med, 52, 1313, 10.2967/jnumed.111.089953 · DOI

Cited by

See all 92

Metadata

Authors
Nord, M., Finnema, S. J., Halldin, C., & Farde, L.
Venue
International Journal of Neuropsychopharmacology
Published
2013-08-01
Volume
16
Issue
7
Pages
1577-1586
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2163858318
Cited by
92
References
6
FWCI
4.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. https://app.cochat.ai/papers/10.1017/s1461145712001617
The paper
Nord, M., Finnema, S. J., Halldin, C., & Farde, L. (2013). Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145712001617

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.